# ERX1000 - Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Male and Female Subjects With Obesity

> **NCT04890873** · PHASE1 · COMPLETED · sponsor: **ERX Pharmaceuticals** · enrollment: 48 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** ERX1000
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04890873
- **Lead sponsor:** ERX Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-17
- **Primary completion:** 2023-07-03
- **Final completion:** 2023-07-03
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2023-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04890873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04890873, "ERX1000 - Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Male and Female Subjects With Obesity". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT04890873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*